Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA. (Q38061168)

28 August 2017

1 reference

title

Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA. (English)

1 reference

28 August 2017

gram-positive bacteria

0 references

author name string

Mark W Garrison

series ordinal

1

1 reference

PubMed ID

23167512

28 August 2017

Nathan M Kawamura

series ordinal

2

1 reference

PubMed ID

23167512

28 August 2017

Mary M Wen

series ordinal

3

1 reference

28 August 2017

1 October 2012

1 reference

Expert Review of Anti-infective Therapy

28 August 2017

1 reference

28 August 2017

10

1 reference

28 August 2017

10

1 reference

28 August 2017

1087-1103

1 reference

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

28 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Invasive methicillin-resistant Staphylococcus aureus infections in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Recommendations for preventing the spread of vancomycin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Vancomycin resistance in staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Antibiotic options for treating community-acquired MRSA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Activity of ceftaroline against serotyped Streptococcus pneumoniae isolates from Europe and South Africa associated with community-acquired bacterial pneumonia (2007-08).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Evaluation of the in vivo efficacy of intramuscularly administered ceftaroline fosamil, a novel cephalosporin, against a methicillin-resistant Staphylococcus aureus strain in a rabbit endocarditis model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid a

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

A prediction rule to identify low-risk patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Effect of ceftaroline on normal human intestinal microflora.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.112

21 January 2018

Identifiers

DOI

10.1586/ERI.12.112

1 reference

28 August 2017

1 reference

PubMed ID

23167512